Literature DB >> 1391976

Genetic evolution of breast cancer: II. Relationship with estrogen and progesterone receptor expression.

H Magdelenat1, M Gerbault-Seureau, C Laine-Bidron, M Prieur, B Dutrillaux.   

Abstract

The expression of estrogen (ER) and progesterone (PR) receptors was assayed by steroid binding in a series of 95 malignant breast tumors, for which the analysis of chromosome aberrations was performed and allowed the reconstruction of their chromosomal evolution. It was shown that breast tumors undergo a progressive loss of chromosomes, with occasionally one and rarely two endoreduplications. Chromosome losses were often the consequence of rearrangements, and the rate of rearranged chromosomes, which increases progressively, appeared as a possible indicator of tumor progression. The distribution of ER and PR values in the sample of 95 tumors was compared to that of a larger control series of consecutive cases: 598 for ER and 460 for PR. The similarities of the distributions indicated that the sample of 95 tumors was representative of the general population of breast cancers. The levels of ER and PR expression were very strongly and negatively correlated to the rate of rearranged chromosomes, but not to the modal number of chromosomes. However, when tumors having either undergone endoreduplication or not (greater than 50 or less than 51 chromosomes, respectively) were considered separately, a significant correlation between ER and PR expression and chromosome number was found within each group. Finally, breast cancers were subdivided into 4 stages of cytogenetic evolution, from the least to the most evolved: stage 1: less than or equal to 50 chromosomes, less than 25% rearranged chromosomes; stage 2: greater than 50 chromosomes, less than 25% rearranged chromosomes; stage 3: less than or equal to 50 chromosomes, greater than 25% rearranged chromosomes; stage 4: greater than 50 chromosomes, greater than 25% rearranged chromosomes.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1391976     DOI: 10.1007/bf01833341

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  12 in total

Review 1.  Steroid receptors, cellular kinetics, and lymph node status as prognostic factors in breast cancer.

Authors:  S E Benner; G M Clark; W L McGuire
Journal:  Am J Med Sci       Date:  1988-07       Impact factor: 2.378

2.  Breast cancer genetic evolution: I. Data from cytogenetics and DNA content.

Authors:  B Dutrillaux; M Gerbault-Seureau; Y Remvikos; B Zafrani; M Prieur
Journal:  Breast Cancer Res Treat       Date:  1991-11       Impact factor: 4.872

3.  Cytogenetic study of twelve human near-diploid breast cancers with chromosomal changes.

Authors:  M Gerbault-Seureau; P Vielh; B Zafrani; R Salmon; B Dutrillaux
Journal:  Ann Genet       Date:  1987

4.  Revision of the standards for the assessment of hormone receptors in human breast cancer; report of the second E.O.R.T.C. Workshop, held on 16-17 March, 1979, in the Netherlands Cancer Institute.

Authors: 
Journal:  Eur J Cancer       Date:  1980-11       Impact factor: 9.162

5.  Progesterone receptor as a more reliable prognostic parameter than estrogen receptor in patients with advanced breast cancer.

Authors:  H Magdelénat; P Pouillart; M Jouve; T Palangié; E Garcia Giralt; B Bretaudeau; B Asselain
Journal:  Breast Cancer Res Treat       Date:  1982       Impact factor: 4.872

6.  Progesterone and estrogen receptors as prognostic variables in breast cancer.

Authors:  B H Mason; I M Holdaway; P R Mullins; L H Yee; R G Kay
Journal:  Cancer Res       Date:  1983-06       Impact factor: 12.701

7.  [Determination of estrogen receptors in 160 breast tumors using monoclonal antibodies: comparison of Abbott's immunoenzymatic method with the carbon dextran method].

Authors:  J Goussard; C Lechevrel; P M Martin; G Roussel
Journal:  Bull Cancer       Date:  1985       Impact factor: 1.276

8.  Estrogen receptor content and ploidy of human mammary carcinoma.

Authors:  P Bichel; H S Poulsen; J Andersen
Journal:  Cancer       Date:  1982-11-01       Impact factor: 6.860

Review 9.  [Drill biopsy and puncture biopsy for the determination of hormone receptors].

Authors:  H Magdelenat
Journal:  Pathol Biol (Paris)       Date:  1983-11

10.  Prolonged G2 phase of breast cancer cells and chromosome damage.

Authors:  B Dutrillaux; M Gerbault-Seureau; B Zafrani; M Prieur
Journal:  Eur J Cancer       Date:  1991       Impact factor: 9.162

View more
  4 in total

1.  Proliferative activity of breast cancers increases in the course of genetic evolution as defined by cytogenetic analysis.

Authors:  Y Remvikos; M Gerbault-Seureau; H Magdelénat; M Prieur; B Dutrillaux
Journal:  Breast Cancer Res Treat       Date:  1992       Impact factor: 4.872

2.  Genetic evolution of breast cancers. III: Age-dependent variations in the correlations between biological indicators of prognosis.

Authors:  Y Remvikos; H Magdelenat; B Dutrillaux
Journal:  Breast Cancer Res Treat       Date:  1995-04       Impact factor: 4.872

3.  Prognostic value of the S-phase fraction of breast cancer.

Authors:  Y Remvikos
Journal:  Br J Cancer       Date:  1993-08       Impact factor: 7.640

4.  Homogeneously staining regions in 223 breast carcinomas: cytogenetic and clinicopathological correlations.

Authors:  J Bernardino; M Gerbault-Seureau; B Zafrani; Y Dericke; E Boudou; H Magdelenat; B Dutrillaux
Journal:  Br J Cancer       Date:  1998-11       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.